Table 1.

Population Inputs

Model Parameter	Value	Source
Population inputs
Age at transplantation, yr	53	CIBMTR [3]
Male sex, %	58	CIBMTR [14]
Malignancy or underlying disease, %
AML	51	CIBMTR [3]
ALL	21
MDS	28
SCT donor type and graft source, %
Related	32
Bone marrow	8
PBSCs	92
Unrelated	68
Bone marrow	9
PBSCs	91
Healthcare utilization costs, $
Cost of allo-HCT	182,642	Grubb et al. 2016 [21]
Acute GVHD
100 days	79,197	Yu et al. 2020 [22]
1 year	158,938
Chronic GVHD (1 year)	220,202	Bachier et al. 2021 [19]
Relapse episode	206,003	Pandya et al. 2019 [24]
Infection-related hospitalization	53,214	Godara et al. 2021 [25], Schuster et al. 2017 [26]
Maintenance therapy
Annual cost of sorafenib	277,765	IBM Redbook [29], Nexavar PI [30]
Annual cost of imatinib mesylate	184,861	IBM Redbook [29], Gleevec PI [31]
End of life	174,102	Mau et al. 2020 [32], Scitovsky et al. 2005 [33]
Patient utilities and disutilities
Utilities
Post-HCT without GVHD	0.86	Perić et al. 2016 [35], Forsythe et al. 2018 [36]
Post-HCT with GVHD	0.69
Relapse/progressed
AML	0.53	Pan et al. 2010 [42]
ALL	0.74	Delea et al. 2017 [43]
MDS	0.60	Pan et al. 2010 [42]
Disutilities
Infection	−0.23	Sarkar et al. 2019 [37]

All costs are inflation-adjusted to 2021 US dollars using the using the medical care consumer price index from the Bureau of Labor Statistics [34]. PBSCs indicates peripheral blood stem cells.